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Abstract 
Objective: To explore whether ocular vestibular evoked myogenic potentials (oVEMP) 
can be used to detect a decrement in the extraocular muscle activity of myasthenia 
gravis (MG) patients.  
Methods: Twenty-seven MG patients, including 13 with isolated ocular and 14 with 
generalized MG and 28 healthy subjects participated. We applied repetitive vibration 
stimuli to the forehead and recorded the activity of the inferior oblique muscle with two 
surface electrodes placed beneath the eyes. To identify the oVEMP parameters with the 
highest sensitivity and specificity, we evaluated the decrement over 10 stimulus 
repetitions at three different repetition rates (3Hz, 10Hz and 20Hz). 
Results: Repetitive stimulation at 20Hz yielded the best differentiation between MG 
patients and controls with a sensitivity of 89% and a specificity of 64% when using a 
unilateral decrement of ≥15.2% as cut-off. When using a bilateral decrement of ≥20.4% 
instead, oVEMP allowed differentiation of myasthenia gravis from healthy controls with 
100% specificity, but slightly reduced sensitivity of 63%. For both cut-offs, sensitivity 
was similar in isolated ocular and generalized MG.  
Conclusions: Our study demonstrates that the presence of an oVEMP decrement is a 
sensitive and specific marker for MG. This test allows direct and non-invasive 
examination of extraocular muscle activity, with similarly good diagnostic accuracy in 
ocular and generalized MG. Thus, oVEMP represents a promising diagnostic tool for 
MG.  
Classification of Evidence: This study provides Class III evidence that oVEMP testing 
accurately identifies patients with MG with ocular symptoms (sensitivity 89%, specificity 
64%).  
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Abbreviations: AChR = acetylcholine receptor; MG = myasthenia gravis; RNS = 
repetitive nerve stimulation; oVEMP = ocular vestibular evoked myogenic potentials; IO 
= inferior oblique muscle. 
 
Introduction  
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by defective 
neuromuscular transmission.1 The clinical hallmark is a fluctuating, exercise-dependent 
and usually reversible muscle fatigability. About 85% of the patients initially demonstrate 
only ocular symptoms, but the disease generalizes in up to 80%, usually within 1 year.2 
Early diagnosis of this potentially lethal disorder is important,3 as early 
immunosuppressive treatment of ocular MG may reduce the risk of generalization.4,5 
Nevertheless, up to 46% of patients do not receive the correct diagnosis within the first 
year of onset.6,7  
The most common ancillary tests include antibody assays, electrophysiological tests 
(repetitive nerve stimulation, RNS or single-fiber electromyography, SFEMG) and 
edrophonium test. In isolated ocular MG, however, these tests exhibit a reduced 
sensitivity.8  
Correct evaluation of ocular symptoms is critical for shortening the diagnostic delay in 
MG. However, the extraocular muscles have previously not been directly accessible for 
clinical testing. We therefore assessed an additional application of a vestibular test – 
ocular vestibular-evoked myogenic potentials (oVEMP) – for measuring the 
pathognomonic decrement of extraocular muscle activity in MG. OVEMPs are a recently 
developed test that records electromyographic activity of the inferior oblique muscle 
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(IO).9-13 Originally, the test was designed to assess otolith function.14,15  Here, we set out 
to demonstrate the utility of oVEMP to detect the decrement in extraocular muscle 
surface-EMG of MG patients. Compared to other tests, oVEMP would be a unique tool 
in ocular MG, as it may directly and non-invasively reveal the pathognomonic fatigability 
of extraocular muscles. 
 
Methods  
Standard Protocol Approvals, Registrations, and Patient Consents 
This prospective study was conducted at the Departments of Ophthalmology and 
Neurology, University Hospital Zurich, Switzerland. The Canton Zurich Ethics 
Committee approved the protocol (KEK-ZH-Nr 2010-0177). We obtained informed 
written consent from all participants and an authorization-for-disclosure for figure and 
video from all recognizable participants in accordance with the Helsinki Declaration. The 
primary purpose of the study was to provide Class III evidence that oVEMP accurately 
differentiates between MG patients with ocular symptoms and healthy subjects. 
 
Subjects 
We included 27 MG patients (mean age 58, range 26-86) with ocular involvement (table 
e-1). All patients had ocular symptoms, including ptosis (100%) and diplopia (85%). 
Thirteen patients (48%) had isolated ocular MG and 14 patients (52%) generalized MG. 
Diagnosis of MG was made based on the presence of a typical history and at least one 
positive ancillary test, including edrophonium testing, RNS and serum autoantibodies 
(anti-AChR, anti-Titin, anti-MuSK). We included a control group of 28 healthy subjects 
(mean age 47, range 21-86) without any neuromuscular, vestibular or oculomotor 
Valko et al.      6 
 
disorders. All patients but one were already on pyridostigmine treatment, which was 
interrupted overnight in 21 patients and 4-5 hours prior to testing in 5 patients. We did 
not include subjects with known vestibulocochlear disorders, as oVEMP signals may not 
be elicited in these patients. The oVEMP results of three control subjects and one 
patient were not analyzable due to excessive blink artifacts and were excluded.  
 
Equipment 
Subjects lay supine with their head on a pillow. The skin was cleaned with abrasive gel 
(Nuprep, USA) before surface electrodes (Blue sensor N, Ambu, Denmark) were 
applied beneath the eyes. For each eye an active electrode was placed over the infra-
orbital margin and a reference directly below on the cheek (figure 1). We placed a 
ground electrode on the chin. OVEMPs were elicited by bursts of bone-conducted skull 
vibration delivered with a hand-held ‘minishaker’ positioned over the hairline (minishaker 
4810; amplifier 2706, Bruel and Kjaer, Naerum, Denmark) (video 1). Stimulus 
generation and surface EMG recording was done with laboratory data acquisition 
devices (power 1401, 1902 pre-amplifier, CED, UK). Signals were bandpass filtered 
(5Hz-2000Hz) and sampled at 10kHz with sweep-based recording software (Signal, 
version 5, CED, UK). To reduce possible electro-magnetic interference with the 
recordings, the minishaker was shielded with a µ-Metal encasement (figure 1).  
 
Recording 
We delivered 4ms bursts of 500Hz bone-conducted vibration in trains of ten stimuli 
(video 1). The ten stimuli were given at three different repetition rates of 3, 10 and 
20Hz. We usually started with the 3Hz paradigm and ended with the 20Hz paradigm. To 
avoid fatigue during the test, we ensured that the patients had breaks of at least 2 
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minutes between tests. For each paradigm we delivered 20-30 repetitions of trains with 
ten stimuli while the subjects were looking up. Trains were separated by 5s of rest, 
during which subjects closed their eyes for 3s. 
The oVEMP signal consists of at least two peak-trough sequences (figure 2). The first 
peak-trough (n10-p15) is a vestibular-dependent reflex of the IO originating from the 
contralateral ear.9 The second peak-trough is also predominantly vestibular, but 
probably originates from both ears. 
 
Data processing and statistics 
The study results are reported in accordance with the Standards for Reporting of 
Diagnostic Accuracy Studies (STARD) (figure e-1). Analysis of oVEMP data was 
performed using MatLab (MathWorks, Natick, MA, USA). Residual main artifacts were 
removed using a 50Hz notch filter (Q factor=10), occasional electrooculographic eye 
movement artifacts after the first trial were removed using a 4th-order Butterworth high-
pass filter with a 20Hz cutoff-frequency. Minimal distortion of the filtered oVEMP signal 
was ensured by comparison to the raw signal. Signal repetitions were averaged after 
outliers were removed with a median absolute deviation (MAD) algorithm, 
complemented by visual inspection. Mean rejection rates in patients and controls were 
similar (18±14% vs. 15±11%).  
Statistical analyses were performed using IBM SPSS (version 22.0, USA). Group data 
were described by means and standard deviations, unless otherwise specified. For 
average comparison of normally distributed data, we used unpaired Student’s t-tests. To 
compare mean decrements between more affected and less affected eyes, we used 
paired t-tests.16 The chi-square test was used for nominal data. For non-parametric 
data, we applied the Mann-Whitney U-test. We calculated Spearman's rank coefficient 
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for correlation analysis of non-normally distributed data. To determine optimal oVEMP 
cut-off values, we applied receiver operating characteristics (ROC). Significance was 
accepted at p<0.05. 
 
Results 
Patient characteristics 
Table e-1 gives an overview on demographic, clinical and diagnostic characteristics of 
the 27 MG patients. AchR-antibodies were positive in 20/27 tested patients (74%), titin-
antibodies in 8/23 tested patients (35%), and MuSK-antibodies in 1/21 tested patients 
(5%). Seven patients (26%) had negative results in all three antibody assays, with six of 
them having isolated ocular MG. Edrophonium test was positive in 16/18 patients 
(89%), while one patient had only subjective improvement of diplopia and one showed 
no improvement of diplopia. Both of these patients (11%) had isolated ocular MG. In 7 
patients (26%) CT thorax revealed thymoma. All of them, and 4 patients without 
thymoma, underwent thymectomy (11 patients, 41%).  
 
OVEMP in MG 
OVEMP responses were present in all patients and controls. They consisted of a series 
of peaks and troughs and the second peak and trough were generally largest. Therefore 
we used the peak-to-peak amplitude of this second biphasic wave to measure any 
decrement over the stimulus trains. Figure 2 illustrates oVEMP recordings from an MG 
patient and a control subject explaining the decrement calculation method. We defined 
the decrement as the difference between the second oVEMP response and the average 
of the fifth to ninth responses. The first oVEMP response showed an increased 
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amplitude with high variability in healthy controls. Therefore we used the second 
response as reference. Next we explored which repetition rate was best to discern 
patients from controls (figure 3). Mean decrements did not differ between patients and 
controls when stimulating with 3Hz (-11.6%±17.8 vs. -7.7%±15.4, p=0.23) and 10Hz (-
5.4%±28.1 vs. -1.7%±16.7, p=0.41). Conversely, at 20Hz the mean decrement in 
patients was larger than in controls (-21.5%±29.6 vs. -2.8%±16.9, p<0.001). As shown 
in table e-1, interindividual variability in decremental responses of patients was high, 
but intraindividual correlation (left vs. right eye) of oVEMP decrements was robust 
(r=0.614, p=0.001).  
Using ROC analysis, we identified optimal decrement cut-offs for distinguishing patients 
from normal subjects (figure 4). To account for the fact that each subject contributed 
two measurements (one for each eye)16, we explored two different decrement types: 
unilateral decrement (where at least one of the two eyes showed a decrement) and 
bilateral decrement (where both eyes showed a decrement). For the unilateral analysis, 
only the eye with the larger decrement was considered. For the bilateral analysis, only 
the eye with the smaller decrement was considered, as this eye sets the threshold for 
bilateral involvement. Stimulation at 20Hz had superior diagnostic yields than 3Hz and 
10Hz. ROC analysis revealed that in 20Hz trains a unilateral decrement of ≥15.2% had 
a sensitivity of 89% and a specificity of 64% (24 patients and 10 controls with unilateral 
decrement ≥15.2%, p<0.001). Instead, when using a bilateral decrement of ≥20.4% as 
cut-off, specificity was 100% and sensitivity 63% (17 patients with bilateral decrement 
≥20.4% and 0 controls, p<0.001). There was no correlation between the magnitude of 
decrement and age, and mean age was similar in patients with and without bilateral 
decrement (59±17 vs. 55±17, p=0.49). 
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Isolated ocular MG 
The diagnostic yield of antibody assays and RNS was lower in patients with isolated 
ocular MG compared to patients with generalized MG (table 1). The frequency of 
positive oVEMP findings, however, was similar in both groups. Specifically, twelve 
patients with isolated ocular MG and twelve patients with generalized MG showed a 
unilateral decrement of ≥15.2%, yielding a comparable sensitivity of 92% and 86% 
(p=1.00). Likewise, a bilateral decrement of ≥20.4% showed a sensitivity of 62% in 
ocular and 64% in generalized MG (p=0.60).  
 
Clinical symptoms and oVEMP findings 
In all but one patient, ptosis was asymmetric, with unilateral predominance in 16 
patients and strictly unilateral manifestation in 11 patients. MG patients had more 
pronounced oVEMP decrements on the clinically (more) affected eye compared to the 
less or not affected eye (-27.4%±26.0 vs. -16.2%±33.2, p=0.03). On the other hand, 
patients without overt ophthalmoparesis (n=4) had similar oVEMP findings as those with 
diplopia (n=23) (-18.8±32.2% vs. -21.9±29.5%, p=0.79). In two patients the clinical 
involvement was evident in one eye only (unilateral ptosis, no diplopia), but oVEMP 
revealed a bilateral decrement ≥20.4% in both cases. 
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Discussion  
This is a proof of principle study with Class III evidence that oVEMP testing accurately 
identifies MG patients with ocular symptoms. We have demonstrated that a reflex of the 
extraocular muscles decreases with repetitive vestibular stimulation using oVEMP 
technique, similar to RNS. The test yielded a sensitivity of 89% and a specificity of 64% 
with a unilateral decrement of ≥15.2%. Instead, when using a bilateral decrement of 
≥20.4% as cut-off, oVEMP allowed differentiation between MG and healthy controls with 
100% specificity, however at the cost of reduced sensitivity of 63%. While traditional 
diagnostic procedures suffer from reduced sensitivity in ocular compared to generalized 
MG,8,17 the sensitivity of oVEMPs appears equally high in isolated ocular MG, as this 
test directly assesses the decrement in extraocular muscle EMG. Specifically, 12/13 
patients with isolated ocular MG and 12/14 patients with generalized MG showed a 
unilateral decrement of ≥15.2%, yielding a comparable sensitivity of 92% and 86%. 
Similarly, a bilateral decrement of ≥20.4% showed a sensitivity of 62% in ocular and 
64% in generalized MG. Hereby, we demonstrated the diagnostic utility of oVEMP in 
MG with ocular involvement. 
The oVEMP has only recently been introduced into clinical practice to test otolith 
function in vestibular disorders. The test is based on the vestibulo-ocular reflex (VOR) 
and allows examination of brisk extraocular muscle activation after vestibular otolith 
stimulation.11,13,14 Most probably, all extraocular muscles receive neural projections from 
the otoliths. However, using simultaneous surface and needle recordings of the IO, we 
recently identified the IO as the principal origin of the excitatory potentials measured by 
the surface recordings in the clinical oVEMP.9 Any structural lesion between otoliths and 
extraocular muscles likely affects oVEMP characteristics. Clinical application has 
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produced two types of pathological oVEMP results: 1) the amplitude of potentials may 
be reduced or absent as in acute vestibular neuritis18, or 2) the dynamics of potentials 
may be delayed as in inflammatory or neurodegenerative CNS conditions (multiple 
sclerosis or Parkinson’s disease).19,20 The present study, however, demonstrates a third 
electrophysiological dimension of oVEMPs, namely the capability of measuring the 
pathognomonic decrement in extraocular muscles of MG patients. 
Using ROC analysis we found that repetitive stimulation with 20Hz trains provided 
higher discriminatory power than lower repetition rates (3Hz and 10Hz trains). The 
possibility to apply fast repetition rates is one important advantage of oVEMP, which is 
not possible by measuring voluntary saccadic eye movements.21,22 As a consequence, 
oVEMP allowed us to unmask myasthenic decrements even in clinically asymptomatic 
eyes. We defined the oVEMP decrement as the reduction between the second stimulus 
and the average of the fifth to ninth stimuli. For reasons to be investigated, the first 
stimulation produced an increased amplitude with high variability in healthy controls, 
while the second response was sometimes larger than the first at high repetition rate in 
MG patients. Superimposition of subtle blink artifacts may in part account for this effect, 
although analysis of all patients’ and controls’ curves demonstrated such effects also in 
the absence of obvious blink artifacts. The fluctuations observed during the first two 
stimuli may reflect facilitation effects, possibly caused by acetylcholine quantal 
release.23 For these reasons, we preferred to use the second peak as reference value 
to avoid any bias by differently enlarged first peaks. 
A critical question concerns the differential discriminatory power of a unilateral vs. 
bilateral decrement. The advantage of unilateral decrement is gain in sensitivity, which 
may be particularly desirable when evaluating patients with very mild symptoms. On the 
other hand, the advantage of using a bilateral decrement is its high specificity, which is 
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on a par with the 94-99% specificity described for other methods including antibody 
assays and RNS.24 The cause of occasional unilateral decrements in controls remains 
unclear, but artifacts due to positioning of the mini-shaker should be considered. Little is 
known about the variability in disease severity between individual extraocular muscles, 
but our oVEMP measurements may have failed to detect a decrement if the myasthenic 
process spared the IO. Thus, technical improvements enabling recordings from 
additional extraocular muscles may improve oVEMP sensitivity in ocular MG even 
further. 
Compared to other diagnostic tests for MG, oVEMP has several merits. Antibody 
assays and RNS are highly specific, but have low sensitivities in ocular MG. For 
instance, an overview of six studies assessing the diagnostic accuracy of anti-AChR 
antibodies found sensitivities of 87-98% in generalized MG but only 39-71% in ocular 
MG.24 Similarly, six of our ocular MG patients were “triple-seronegative”, including three 
patients with no decrement in RNS, yet five of them had positive oVEMP results, thus 
highlighting the diagnostic usefulness of oVEMP in this challenging subgroup. 
The sensitivity of RNS in ocular MG is even lower, ranging between 11-39%.24 In ocular 
MG, SFEMG is considered the diagnostic gold standard, as reflected by four studies 
reporting a high sensitivity of 92-97%25-28, although two other groups found lower 
sensitivities of 83% and 62%.29,30 Comparison of different electromyographic tests in 
ocular MG demonstrated that the closer the measurement to the extraocular muscles, 
the higher the sensitivity. In contrast to SFEMG, oVEMP not only directly assess the 
extraocular muscles, but is also better tolerated, because it is less invasive, less 
cumbersome and less operator-dependent. 
OVEMP also has several advantages over the edrophonium test. Edrophonium testing 
is limited to patients with observable deficits (e.g. ptosis, diplopia) and is contraindicated 
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in cardiac or respiratory disease. In addition, the drug is not registered in many 
countries and therefore often unavailable outside university hospitals. 
Our study suggests that oVEMP bypasses many of the above-mentioned limitations, as 
its diagnostic sensitivity seems less susceptible to the immunological and clinical 
heterogeneity in MG. In other words, oVEMP gives direct evidence of the myasthenic 
decrement in affected extraocular muscles, irrespective of the exact underlying 
immunologic process. Therefore, oVEMP is suitable to become an integral diagnostic 
part in the routine evaluation of patients with suspected MG. 
Since the main purpose of the study was proof of principle, we used a case-control and 
not a cohort study design. In other words, we provide Class III evidence of the capability 
of oVEMP to distinguish between MG patients and healthy controls, but future studies 
will need to confirm its diagnostic utility in clinical practice, when the main challenge is 
differentiation from patients with other neuro-ophthalmological conditions. Second, we 
studied patients with previously established diagnoses because we wanted to validate 
our oVEMP measurements in MG. A consequence was that all patients but one were 
already under treatment with cholinesterase inhibitors, although oVEMP was usually 
performed in the morning prior to the first drug intake of the day. Therefore it remains 
unclear what the diagnostic accuracy of oVEMP would be in drug-naïve patients, though 
it can be speculated that more pronounced muscle fatigability would actually enhance 
the sensitivity of oVEMP, similar to the treatment effects on RNS in generalized MG.31,32 
Third, ophthalmoparesis was rather mild in our patients and it remains to be determined 
to what extent severe limitation in upward gaze may interfere with oVEMP testing. 
Fourth, we did not randomize the sequence of the tests, but performed the 3Hz test first, 
and the 20Hz test at the end. Nevertheless, the tests were short and patients had 
breaks between the tests, so that a potential sequence-induced bias due to a 
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cumulative fatigue effect should be minimal. Finally, our control group was slightly 
younger, and small age-related effects on oVEMP have been described.33,34 
Nevertheless, we did not find any correlation between the magnitude of decrement and 
age, and mean age was similar in patients with and without bilateral decrement. 
Our findings indicate that oVEMP has the potential to play a helpful role in the diagnosis 
of ocular MG. Compared to other diagnostic procedures, oVEMP has the unique 
advantage of providing direct evidence of the myasthenic process in affected 
extraocular muscles. Technical advances and optimization in signal detection from as 
many different extraocular muscles as possible will likely further increase the sensitivity 
of oVEMP in MG. Finally, oVEMP is a simple, non-invasive and fairly inexpensive tool 
that can be linked to any standard EMG equipment and therefore easily implemented in 
any clinical electrophysiology unit. 
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Figure legends 
Figure 1. Experimental setup for oVEMP recording.  
Recording is performed in sustained upgaze as in the ‘Simpson test’ thus activating the 
superior rectus and inferior oblique muscles in both eyes. A minishaker at the hairline of 
the forehead delivers the bone-conducted vibration stimulus. Active (black) and 
reference (red) electrodes measure the surface EMG signal from the inferior oblique 
muscles; ground electrode (green) is on the chin. 
Figure 2. OVEMP recordings in a myasthenic patient (A) and in a normal subject 
(B).  
The grey bars indicate the 10 stimuli at 20Hz repetition rate, which are followed by 
characteristic oVEMP signals. OVEMP signals are averaged from 20-30 responses. 
The magnitude of each oVEMP signal was calculated as the sum of the second peak 
and second trough (asterisks). The magnitude of the decrement (C) was calculated as 
the difference between the amplitude of the second stimulation and the mean amplitude 
of the fifth to ninth stimulations. 
Figure 3. Group comparison between MG patients and controls at three different 
repetition rates. 
The mean oVEMP responses of the first nine stimulations are shown for each 
paradigm. Each oVEMP response is indicated as normalized value ± 1 SD with respect 
to the second stimulation as reference. Mean decrement was similar in MG patients 
(red) and controls (blue) when applying trains of 3Hz (A) and 10Hz (B). Only repetitive 
stimulation at 20Hz (C) allowed reliable group differentiation, as indicated by the 
significantly larger decrement in MG patients than in controls. 
Figure 4. Receiver-operating characteristic curve (ROC) analyses to determine 
optimal cut-off. 
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The box plots in the upper row compare the distribution of subjects. The dotted red lines 
indicate the optimal diagnostic thresholds for unilateral (A) and bilateral (B) decrement, 
as derived from the ROC analyses shown in the lower row (C, D). For the unilateral 
decrement, we analyzed and plotted the eye with the larger decrement (A, C). For the 
bilateral decrement, we analyzed and plotted the eye with the smaller decrement (B, D), 
as this eye sets the threshold for bilateral involvement. The boxes show median (red 
line), first and third quartiles, while the end of the whiskers represent the most extreme 
data points without outliers. For both unilateral (C) and bilateral (D) decrements, the 
area under the curve (AUC) was larger at 20Hz (red) than at 3Hz (green) and 10Hz 
(blue). At 20Hz a unilateral decrement of ≥15.2% has the advantage of a high sensitivity 
of 89% with only three false-negative cases, while a bilateral decrement of ≥20.4% has 
an excellent specificity of 100% without any false-positive cases. 
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Table 1. Comparison of demographical, clinical and diagnostic characteristics between 
patients with isolated ocular MG and generalized MG. While the diagnostic yield of 
antibody assays and repetitive nerve stimulation is lower in patients with isolated ocular 
MG than in generalized MG, the sensitivity of oVEMP does not differ, making it hence a 
valuable test in patients lacking non-ocular symptoms.  
 
Isolated ocular MG 
(n = 13) 
Generalized MG 
(n = 14) 
 p 
    Age, y 49 ± 14 66 ± 15 0.01 
Gender, female 6 / 13 (46%) 3 / 14 (21%)  0.17 
Disease duration, months 40 ± 63 38 ± 43 0.93 
Diagnostic delay, months 0.9 ± 1.2 1.7 ± 2.1 0.24 
    Antibody assays    
AChR-ab, pos 7 / 13 (54%) 13 / 14 (93%) 0.03 
Titin-ab, pos 1 / 10 (10%) 7 / 13 (54%)  0.04 
MuSK-ab, pos 0 / 9   1 / 12 (8%) 0.57 
All antibodies neg 6 /13 (46%) 1 / 14 (7%) 0.03 
    Repetitive nerve stimulation    
Positive decrement  3 / 7 (43%) 6 / 6 (100%) 0.049 
    Edrophonium test    
Positive  7 / 9 (78%)  9 / 9 (100%)  0.24 
    oVEMP findings    
Uni- or bilateral decrement ≥15.2% 12 / 13 (92%) 12 / 14 (86%) 1.00 
Bilateral decrement ≥20.4% 8 / 13 (62%)  9 / 14 (64%) 0.60 
Decrement, magnitude -27.2 ± 23.9 -16.1 ± 33.5 0.17 
    
 
Table e-1 Demographic, clinical and diagnostic characteristics of the 27 patients with myasthenia gravis 
Patient Age /  Disease Clinical manifestation  Antibodies  Repet. nerve stim.  Tensilon  Thy-      Thym-      Drug   oVEMP-decr. (%) 
 gender  duration ptosis  diplopia  bulbar  limbs AChR Titin MuSK decr. nerv      test        moma   ectomy     treatment   right (20Hz)  left 
  1* 70 / F  5m  L > R + - - + + n.d. + XI         n.d.        -           -            P    -17.0     -11.9 
  2* 49 / F 10m  R /  - - - - + - - + Uln.          n.d.        -          +            P S   -21.1     -40.4 
  3* 66 / F  9m  L > R + - - + n.d. n.d. - VII, XI, Uln.     -         -           -            P S A   -21.0     -49.8 
  4* 60 / M 4m  -  /      L + - - + n.d. n.d. n.d. n.d.         n.d.        -           -            P    -6.6     -16.0 
  5* 51 / F 4y, 7m R /  - + - - + n.d. n.d. n.d. n.d.         n.d.        +          +            P S A   -30.8     -24.2 
  6* 28 / M 2y  R /  - + - - + - - n.d. n.d.         +         -           -            P    -23.9      39.1 
  7* 36 / F 1y, 6m L > R + - - + - - n.d. n.d.         +         +          +            P S    -9.5      10.0 
  8* 34 / M 4y, 2m R /  - + - - - - - + XI         -/+         -          +            P S   -45.9     -34.4 
  9* 55 / M 5y, 4m -  /     L + - - - - - - XI         +         -           -            P S A    12.7     -63.8 
10* 26 / M 1y  -  /      L + - - - - - - VII         +         -           -            P S A   -48.2     -31.6 
11* 63 / M 20y  R > L + - - - - - - VII, Uln.          +         -          +            P S A   -56.0     -45.2 
12* 47 / M 2y, 4m R > L + - - - - - n.d. n.d.         +         -           -            P S   -58.3     -42.8 
13* 56 / F 3m  R > L + - - - - - n.d. n.d.         +         -           -           (P S)   -24.5     -47.0 
14 47 / F 1y, 4m  R = L + + + + + - + VII, Uln.          +         +          +            P S A   -16.7     -8.9 
15 65 / M 6m  R > L + + + + + - + XI, Uln.           +         -           -            P S   -29.5     -20.4 
16 77 / M 4m  R > L + + - + + - + VII         n.d.        -           -            P S A   -43.7     -26.8 
17 68 / M 10y L > R + + + + + - + XI         n.d.        -          +            P S A   -61.7     -41.7 
18 59 / M 8y, 8m R /  - + + + + + - n.d. n.d.         +         +          +            P S A   -16.1      12.8 
19 73 / F 4m  R /  - + + + + + n.d. n.d. n.d.         +         +          +            P S A   -22.3     -22.4 
20 73 / M 3m  R > L + - + + + - n.d. n.d.         +        (-)           -            P S   -60.7     -28.1 
21 66 / M  1y, 9m L > R - + + + - + n.d. n.d.         n.d.        -          +            P S    45.2      12.7 
22 48 / M 7m  L > R - - + + - - + XI         +         -           -            P S   -45.2     -44.8 
23 54 / M 5y,11m R > L + + - + - - n.d. n.d.         n.d.        +          +            P S A    57.6      85.5 
24 85 / M 9y  R /  - + + - + - - n.d. n.d.         n.d.        -           -            P S   -32.2     -20.4 
25 86 / M 4m  L > R + + + + - - n.d. n.d.         +         +         (+)            P     A   -23.2     -32.8  
26 81 / M 2y, 6m  L > R + + - + n.d. n.d. n.d. n.d.         +         -           -            P S    4.5     -15.2 
27 38 / F 3y   -  /      L - + + - - - + XI         +         -           -            P S   -36.3     -20.7 
AChR = acetylcholine receptor; MuSK = muscle-specific kinase; n.d. = not determined; Uln. = ulnar nerve; (-) = unclear mediastinal lesions in CT thorax; (+) = oVEMP was done prior 
to thymectomy; -/+ = only subjective improvement; P = pyridostigmin; S = steroids; A = azathioprine; (P S) = oVEMP was done prior to treatment; * = isolated ocular myasthenia 
(patients 1-13); bold = decrement ≥15.2%; underlined = bilateral decrement ≥20.4%. 
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Figure e-1. Study flow diagram.
